GlassScriptPhysician profile
Abby Allen
NPI 1497999171
$42,708.46
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $9,598 · 2023: $14K · 2024: $8,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $3,713 · Food and Beverage: $2,673 · Consulting Fee: $2,404 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,095.00 |
| Travel and Lodging | $3,712.73 |
| Food and Beverage | $2,672.60 |
| Consulting Fee | $2,404.04 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $30,265.42 | 2021-2024 | Fasenra, Tezspire, Airsupra |
| Genentech USA, INC. | $9,496.64 | 2021-2024 | Xolair |
| Glaxosmithkline, LLC. | $712.78 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $488.11 | 2021-2024 | Dupixent |
| Genzyme Corporation | $459.98 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $415.27 | 2021-2024 | |
| Pfizer INC. | $237.85 | 2021-2023 | |
| Amgen INC. | $161.61 | 2022-2024 | Tezspire |
| Dermavant Sciences, INC. | $99.61 | 2023 | Vtama |
| Abbvie INC. | $84.18 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Blueprint Medicines Corporation | $42.66 | 2023 | Ayvakit |
| Incyte Corporation | $40.47 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.66 | 2021 | |
| Aimmune Therapeutics, INC. | $33.62 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $29.04 | 2023-2024 | |
| Octapharma USA, INC. | $20.36 | 2023 | Cutaquig |
| Takeda Pharmaceuticals U.S.A., INC. | $17.43 | 2021 | |
| Kaleo, INC. | $14.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.